companies developing glp 1 drugs Lilly is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating The Disruptive Power of Weight

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a leading treatment in the fields of diabetes and obesity, with recent preclinical and clinical studies indicating significant benefits in the management and treatment of MASLD

The index date for this group corresponded to the initial date of their obesity diagnosis

Though modest, it was statistically significant, reinforcing that GLP-1 RAs provide cardiovascular benefit even in a broad diabetes population

When I first started taking it, I was very tired, had no appetite, and felt quite nauseous

Additionally, insurance coverage continues to lag behind clinical evidence, particularly for cardiovascular indications in non-diabetic patients

Players are leveraging investments and expansion opportunities to capitalize on the rising demand for diabetes and obesity treatment